InfuSystem Holdings, Inc
No enriched coverage for $INFU in the last 7 days.
No SEC Form 4 filings for $INFU in the last 30 days.
See all $INFU insider activity →Vaxcyte (PCVX) +31% on positive Phase 3 trial data, $500M stock offering. InfuSystem (INFU) +2% with Q2 revenue $36.9M, FY26 growth 6-8%. Illumina (ILMN) +7% with Q2 revenue $1.59B, FY26 guidance $4.6B-$4.64B. Charles River (CRL) +7% with Q2 revenue $1B, FY26 EPS up $0.25. HeartFlow (HTFL) +5% with Q2 revenue $64.1M, net loss $15.7M.
Omeros (OMER) +13%, Alpha Teknova (TKNO) +5%, BioLife (BLFS) +6%, Schrodinger (SDGR) +4%, and InfuSystem (INFU) +2% hit 52-week highs. OMER reported $32.2M Q2 sales for YARTEMIS. TKNO launched Fill-Tek, with Q2 revenue up 18%. BLFS to be acquired by Repligen (RGEN) for $1.5B, Q2 revenue up 21%. SDGR co-founded Tectora. INFU Q2 revenue $36.9M, up 2.6%.
Diamond Hill Capital's Q2 2026 investor letter reported a 24.01% return, outperforming the Russell 2000. The fund highlighted InfuSystem (INFU), a healthcare services provider, as a new position. INFU closed at $12.18, down 2.48% monthly but up 19.88% yearly, with a $241.79M market cap. The fund cited INFU's unique payer network, profitability improvements, and strong balance sheet as reasons for investment.
Recent INFU coverage spans financial news, market movers and earnings.
Modest upside expected as guidance improves outlook for 2026 earnings.
Guidance lift adds modest support.
Fund initiation may provide modest upside support for INFU.
Earnings call provides fresh operating datapoints and a forward-looking pro forma revenue growth range, with margin expectations anchored to low-to-mid 20% adjusted EBITDA.
Earnings-call disclosures point to improving profitability via the GE contract pivot, offset by device revenue declines and ERP spending taper.
AlphAI scores every news story that mentions INFU with an AI model for sentiment and relevance, and aggregates insider trades from InfuSystem Holdings, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Vaxcyte (PCVX) +31% on positive Phase 3 trial data, $500M stock offering. InfuSystem (INFU) +2% with Q2 revenue $36.9M, FY26 growth 6-8%. Illumina (ILMN) +7% with Q2 revenue $1.59B, FY26 guidance $4.6B-$4.64B. Charles River (CRL) +7% with Q2 revenue $1B, FY26 EPS up $0.25. HeartFlow (HTFL) +5% with Q2 revenue $64.1M, net loss $15.7M.
3 min readOmeros (OMER) +13%, Alpha Teknova (TKNO) +5%, BioLife (BLFS) +6%, Schrodinger (SDGR) +4%, and InfuSystem (INFU) +2% hit 52-week highs. OMER reported $32.2M Q2 sales for YARTEMIS. TKNO launched Fill-Tek, with Q2 revenue up 18%. BLFS to be acquired by Repligen (RGEN) for $1.5B, Q2 revenue up 21%. SDGR co-founded Tectora. INFU Q2 revenue $36.9M, up 2.6%.
2 min readDiamond Hill Capital's Q2 2026 investor letter reported a 24.01% return, outperforming the Russell 2000. The fund highlighted InfuSystem (INFU), a healthcare services provider, as a new position. INFU closed at $12.18, down 2.48% monthly but up 19.88% yearly, with a $241.79M market cap. The fund cited INFU's unique payer network, profitability improvements, and strong balance sheet as reasons for investment.
1 min readInfuSystem (INFU) reported Q2 2026 revenue of $36.9 million, up 2.6% year over year, including a $1.6 million revenue reduction from a GE Healthcare biomedical services contract restructuring. Adjusted EBITDA rose 7.6% to $8.6 million, with margin at 23.4%. Oncology revenue grew 6.4% and Wound Care rose 154%. The company expects 2026 pro forma revenue growth of 6% to 8% and adjusted EBITDA margin in the low-to-mid 20% range.
6 min readInfuSystem Holdings reported Q2 2026 revenue of $36.9 million, up 154% year over year in Wound Care and with 6.4% growth in core Oncology. The company restructured a GE Healthcare biomedical services contract, reducing GAAP revenue by $1.6 million, and raised adjusted EBITDA margin to 23.4%. Guidance keeps pro forma revenue growth at 6% to 8% and EBITDA margins in the low to mid-20% range.
6 min readBiotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.
6 min readInfuSystem Holdings, Inc (INFU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InfuSystem Holdings, Inc. 3851 W. Hamlin Road Rochester Hills, MI 48309 (248) 291-1210 Contact: Barry Steele Chief Financial Officer (248) 260-2211 InfuSystem Announces Financial Results for Second Quarter 2026 Net Revenues of $36.9 million Representing a 2.6% Increa
6 min readHealthcare analysts have provided optimistic insights on InfuSystem Holdings (INFU) and BioMarin Pharmaceutical (BMRN). Craig-Hallum maintained a Buy rating on InfuSystem Holdings with a significant upside, while J.P. Morgan initiated coverage on BioMarin Pharmaceutical with a Buy rating and a set price target. Both companies show strong analyst consensus ratings.
2 min readInfuSystem Holdings, Inc.'s EVP and CIO, Addam Chupa, reported an update to his shareholdings and new equity awards, including 47,210 directly held common shares. He received 9,973 restricted stock units (RSUs) and 20,777 stock options with an exercise price of $8.37 per share. Both the RSUs and stock options begin vesting in equal annual installments starting May 12, 2027.
2 min readInfuSystem Holdings director Beverly A. Huss reported receiving a stock option grant for 24,890 shares, with an exercise price of $8.37 per share. The options will vest on May 12, 2027, and expire on May 12, 2036. This grant represents compensation and not an open-market transaction, adding to her direct holding of 4,300 common shares.
2 min read
